泰嘉在ACSPCI术中的多剂量应用0720幻灯片.pptVIP

This slide places our findings in the context of prior studies of antiplatelet therapy in ACS. The introduction of single antiplatelet therapy with aspirin, as summarized in the APTC report, was associated with a 22% reduction in ischemic events. Moving to dual antiplatelet therapy with clopidogrel + aspirin in CURE produced a further 20% reduction in ischemic events. The higher IPA achieved with the combination of prasugrel and aspirin produced yet a further 19% reduction in ischemic events. Each of these advances in antiplatelet therapy was associated with a progressive increase in major b